Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Alkali or alkaline earth chloride
Reexamination Certificate
2008-05-27
2008-05-27
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Alkali or alkaline earth chloride
C424S722000, C514S879000
Reexamination Certificate
active
10368769
ABSTRACT:
Provided is a novel use of therapeutic concentrations of an inhibitor of glycogen synthase kinase-3 (GSK-3), including lithium or any other GSK-3 inhibitor, to block, reduce or inhibit processing of amyloid precursor proteins to beta-amyloid (Aβ) peptides, which are now believed to be the principal cause of Alzheimer's disease, thereby providing methods useful for the prevention, inhibition or reversal of the disease. Also provided are methods of using agents that specifically target the α isoform of GSK-3, which is responsible for APP processing, making such selective GSK-3α-specific inhibitors especially useful in the treatment, prevention, and possible reversal of Alzheimer's disease. Further provided are kits and screening methods associated with the present methods.
REFERENCES:
patent: 4160152 (1979-07-01), Wightman et al.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4556068 (1985-12-01), Vartsky et al.
patent: 4777049 (1988-10-01), Magruder et al.
patent: 4810497 (1989-03-01), Horrobin
patent: 5252333 (1993-10-01), Horrobin
patent: 6057117 (2000-05-01), Harrison et al.
patent: 6160018 (2000-12-01), Wechter et al.
patent: 6335034 (2002-01-01), Drizen et al.
patent: 6375990 (2002-04-01), Nemeroff et al.
patent: 6441053 (2002-08-01), Klein et al.
patent: 6517859 (2003-02-01), Tice et al.
patent: 2001/0052137 (2001-12-01), Klein
Kalback, W. et al., “APP transgenic mice Tg2576 accumulateAβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's Disease senile plaques,” Biochemistry, vol. 41, pp. 922-928 (2002).
Alvarez, G., et al., “Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium.Possible implications for Alzheimer's disease,”Bipolar Disord.4:153-165 (2002).
Bunny, et al., In:Psychopharmacology: The Third Generation of Progress(Hy, ed.) New York, Raven Press 553-565, date unavailable.
Cook, D.G. et al., “Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/ intermediate compartment of NT2N cells,”Nat. Med.3:1021-1023 (1997).
De Strooper, B. et al., “A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain,”Nature398:518-522 (1999).
De Strooper, B. et al., “Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein,”Nature391:387-390 (1998).
Edbauer, D., et al., “Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation,”Proc. Nat'l. Acad. Sci. USA99:8666-8671 (2002).
Embi, et al., “Glycogen Synthase Kinase-3 from Rabbit Skeletal Muscle,”Eur. J. Biochem.107:519-527 (1980).
Elbashir, S.M. et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,”Nature411:494-498 (2001).
Esler, W.P., et al., “Activity-dependent isolation of the presenilin-gamma-secretase complex reveals nicastrin and a gamma secretase substrate,”Proc. Nat'l. Acad. Sci. U S A99:2720-2725 (2002).
Fagatto, et al., “Binding to Cadherins Antagonizes the Signaling Activity of B-Catenin during Axis Formation inXenopus,” J.Cell Biol.132:1105-1114 (1996).
Forman, M.S., et al., “Differential effects of the Swedish mutant amyloid precursor protein on beta-amyloid accumulation and secretion in neurons and nonneuronal cells,”J. Biol. Chem.272:32247-32253 (1997).
Francis, R., et al., “aph-1 and pen-2 are required for Notch pathway signaling,gamma-secretase cleavage of beta APP, and presenilin protein accumulation,”Dev. Cell3:85-97 (2002).
Genaro, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA (1985).
Goodwin, et al., In:Manic-Depressive Illness, New York Oxford University Press, date unavailable.
Handbook of Dementing Illnesses(John Morris Ed.) Marcel Dekker p. 591 (1994).
Hardy, et al., “Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease,”Aliment. Pharmacol. Therap.1:273-280 (1987).
Harlow and Lane (eds.) In:Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY (1998).
Harwood, et al., “Glycogen Synthase Kinase 3 Regulates Cell Fate in Dictyostelium,”Cell80:139-148 (1995).
Hemmings, et al., “Purification of Glycogen Synthase Kinase 3 from Rabbit Skeletal Muscle,”Eur. J. Biochem.119:445-451 (1982).
Hedgepeth, C. M., et al., “Activation of the Wnt Signaling Pathway: A Molecular Mechanism for Lithium Action,”Devl. Biol.185:82-91 (1997).
Hoeflich, K.P. et al., “Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappa B activation,”Nature406:86-90 (2000).
Hunter, T., et al., “The Protein Kinases of Budding Yeast: Six Score and More,”TIBS22:18-22 (1997).
Iwatsubo, T. et al., “Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals:evidence that an initially deposited species is A beta 42(43),”Neuron13:45-53 (1994).
Jope, et al., “Commentary: Lithium and Brain Signal Transduction Systems,”Biochem. Pharmacol.47:429-441 (1994).
Kang, D.E., et al., “Presenilin couples the paired phosphorylation of beta-catenin independent of axin:implications for beta-catenin activation in tumorigenesis,”Cell110:751-762 (2002).
Kang, D.E. et al., “Presenilin 1 facilitates the constitutive turnover of beta-catenin:differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway,”J. Neurosci.19:4229-4237 (1999).
Kirschenbaum, F., et al., “Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling,”J. Biol. Chem.276:7366-7375 (2001).
Klein, P. S., et al., “A Molecular Mechanism for the Effect of Lithium on Development,”Proc. Natl. Acad. Sci. USA93:8455-8459 (1996).
Korinek, et al., “Constitutive transcriptional activation by a β-Catenin-Tcf complex in APC-/- colon carcinoma,”Science275:1784-1787 (1997).
Leclerc, S. et al., “Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?”J. Biol. Chem.276:251-260 (2001).
Lee, et al., “Secretion and Intracellular Generation of Truncated AB in B-Site Amyloid-B Precursor Protein-Cleaving Enzyme Expressing Human Neurons,”J. Biological Chem., 278(7)4458-4466 (2003).
Leost, M. et al., “Paullones are potent inhibitors of glycogen synthase kinase-3 beta and cyclin-dependent kinase 5/p25,”Eur. J. Biochem.267:5983-5994 (2000).
Miller, et al., “Signal Transduction through B-catenin and Specification of Cell Fate During Embryogenesis,”Genes&Dev.10:2527-2539 (1996).
Phiel, C.J., et al., “Molecular Targets of Lithium Action,”Annu. Rev. Pharmacol. Toxicol.41:789-813 (2001).
Physicians Desk Reference 2352, 2658 (1997).
Pleasure, S.J., et al., “Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons,”J. Neurosic.12:1802-1815 (1992).
Plyte, et al., “Glycogen Synthase Kinase-3: Functions in Oncogenesis and Development,”Biochem. Biophys. Act.1114:147-162 (1992).
Price, et al., “Drug Therapy: Lithium In the Treatment of Mood Disorders,”New Engl. J. Med.331:591-598 (1994).
Ramakrishna, et al., “Effect of Insulin on ATP-Citrate Lyase Phosphorylation: Regulation of Peptide A and Peptide B Phosphorylations,”Biochem.28:856-860 (1989).
Ramakrishna, et al., “Cyclic Nucleotide-independent Protein Kinas from Rate Liver,”J. Biol. Chem.260:12280-12286 (1985).
R
Klein Peter S.
Lee Virginia M-Y.
Phiel Christopher J.
Wilson Christina A.
McConathy Evelyn H.
Montgomery, McCracken, Walker & Rhoads LLP
Pak John
The Trustees of the University of Pennsylvania
LandOfFree
Regulation of GSK-3α activity for the treatment or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulation of GSK-3α activity for the treatment or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of GSK-3α activity for the treatment or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3941120